Methylation of CpG Sites as Biomarkers Predictive of Drug-Specific Patient Survival in Cancer

Bridget Neary; Shuting Lin; Peng Qiu

doi:10.1177/11769351221131124

Methylation of CpG Sites as Biomarkers Predictive of Drug-Specific Patient Survival in Cancer

Cancer Inform. 2022 Nov 2:21:11769351221131124. doi: 10.1177/11769351221131124. eCollection 2022.

Authors

Bridget Neary¹, Shuting Lin¹, Peng Qiu²

Affiliations

¹ School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
² Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.

Abstract

Background: Though the development of targeted cancer drugs continues to accelerate, doctors still lack reliable methods for predicting patient response to standard-of-care therapies for most cancers. DNA methylation has been implicated in tumor drug response and is a promising source of predictive biomarkers of drug efficacy, yet the relationship between drug efficacy and DNA methylation remains largely unexplored.

Method: In this analysis, we performed log-rank survival analyses on patients grouped by cancer and drug exposure to find CpG sites where binary methylation status is associated with differential survival in patients treated with a specific drug but not in patients with the same cancer who were not exposed to that drug. We also clustered these drug-specific CpG sites based on co-methylation among patients to identify broader methylation patterns that may be related to drug efficacy, which we investigated for transcription factor binding site enrichment using gene set enrichment analysis.

Results: We identified CpG sites that were drug-specific predictors of survival in 38 cancer-drug patient groups across 15 cancers and 20 drugs. These included 11 CpG sites with similar drug-specific survival effects in multiple cancers. We also identified 76 clusters of CpG sites with stronger associations with patient drug response, many of which contained CpG sites in gene promoters containing transcription factor binding sites.

Conclusion: These findings are promising biomarkers of drug response for a variety of drugs and contribute to our understanding of drug-methylation interactions in cancer. Investigation and validation of these results could lead to the development of targeted co-therapies aimed at manipulating methylation in order to improve efficacy of commonly used therapies and could improve patient survival and quality of life by furthering the effort toward drug response prediction.

Keywords: DNA methylation; TCGA; drug response biomarkers; drug response prediction; epigenomics; methylation-drug interactions; pharmacoepigenetics; pharmacoepigenomics; precision oncology; survival analysis.